JP2022050400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022050400A5 JP2022050400A5 JP2021199878A JP2021199878A JP2022050400A5 JP 2022050400 A5 JP2022050400 A5 JP 2022050400A5 JP 2021199878 A JP2021199878 A JP 2021199878A JP 2021199878 A JP2021199878 A JP 2021199878A JP 2022050400 A5 JP2022050400 A5 JP 2022050400A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- amino acids
- polypeptide chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 266
- 150000001413 amino acids Chemical class 0.000 claims 96
- 229920001184 polypeptide Polymers 0.000 claims 83
- 108090000765 processed proteins & peptides Proteins 0.000 claims 83
- 102000004196 processed proteins & peptides Human genes 0.000 claims 83
- 238000000034 method Methods 0.000 claims 22
- 239000013604 expression vector Substances 0.000 claims 12
- 238000003259 recombinant expression Methods 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 210000005260 human cell Anatomy 0.000 claims 6
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023221526A JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| US62/369,883 | 2016-08-02 | ||
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
| JP2019505220A JP6993402B2 (ja) | 2016-08-02 | 2017-07-31 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505220A Division JP6993402B2 (ja) | 2016-08-02 | 2017-07-31 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023221526A Division JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022050400A JP2022050400A (ja) | 2022-03-30 |
| JP2022050400A5 true JP2022050400A5 (https=) | 2022-05-30 |
| JP7413338B2 JP7413338B2 (ja) | 2024-01-15 |
Family
ID=59564253
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505220A Active JP6993402B2 (ja) | 2016-08-02 | 2017-07-31 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2021199878A Active JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505220A Active JP6993402B2 (ja) | 2016-08-02 | 2017-07-31 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10611816B2 (https=) |
| EP (2) | EP4159751A1 (https=) |
| JP (4) | JP6993402B2 (https=) |
| KR (1) | KR102527052B1 (https=) |
| CN (2) | CN109790211B (https=) |
| AU (3) | AU2017306038B2 (https=) |
| CY (1) | CY1125601T1 (https=) |
| DK (1) | DK3494133T3 (https=) |
| ES (1) | ES2928051T3 (https=) |
| HR (1) | HRP20221183T1 (https=) |
| HU (1) | HUE060121T2 (https=) |
| IL (2) | IL264425B2 (https=) |
| LT (1) | LT3494133T (https=) |
| PL (1) | PL3494133T3 (https=) |
| PT (1) | PT3494133T (https=) |
| RS (1) | RS63615B1 (https=) |
| SG (2) | SG11201900654QA (https=) |
| SI (1) | SI3494133T1 (https=) |
| SM (1) | SMT202200379T1 (https=) |
| WO (1) | WO2018026691A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018026691A1 (en) * | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EP3684799A1 (en) | 2017-09-20 | 2020-07-29 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Hla class ii restricted t cell receptors against mutated ras |
| AU2018345400B2 (en) | 2017-10-05 | 2024-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| KR20210119468A (ko) * | 2019-01-25 | 2021-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 돌연변이체 ras를 표적화하기 위한 조성물 및 방법 |
| WO2020172332A1 (en) * | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| WO2021092223A1 (en) * | 2019-11-05 | 2021-05-14 | Board Of Regents, The University Of Texas System | Hla restricted hormad1 t cell receptors and uses thereof |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| WO2021135178A1 (zh) * | 2019-12-30 | 2021-07-08 | 华夏英泰（北京）生物技术有限公司 | 一种增强型t细胞受体star及其应用 |
| KR20230058013A (ko) * | 2020-05-25 | 2023-05-02 | 브리스타 이뮤노테크 리미티드 | 향상된 합성 t 세포 수용체 및 항원 수용체 |
| WO2022015694A1 (en) * | 2020-07-13 | 2022-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii–restricted drb t cell receptors against ras with g12d mutation |
| TW202540156A (zh) * | 2020-10-02 | 2025-10-16 | 美國衛生與公眾服務部 | 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體 |
| AU2021381384A1 (en) * | 2020-11-20 | 2023-06-22 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| AU2021388167A1 (en) * | 2020-11-25 | 2023-07-06 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| IL305393A (en) | 2021-02-25 | 2023-10-01 | Alaunos Therapeutics Inc | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| EP4558152A2 (en) * | 2022-07-22 | 2025-05-28 | Board of Regents, The University of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| CN115850444B (zh) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117777270B (zh) * | 2022-09-29 | 2025-04-25 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| AU2023397979A1 (en) * | 2022-12-13 | 2025-07-03 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN120157754A (zh) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
| WO2025259799A2 (en) * | 2024-06-12 | 2025-12-18 | Biontech Us Inc. | T cell receptor compositions and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| AU2008206442B2 (en) | 2007-01-12 | 2012-10-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | gp100-specific T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| ES2635335T3 (es) | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| ES2834070T3 (es) | 2011-09-15 | 2021-06-16 | Us Health | Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7 |
| KR20140100938A (ko) * | 2011-11-30 | 2014-08-18 | 도쿠리츠교세이호진 고쿠리츠간켄큐센터 | 유도 악성 줄기세포 |
| SG11201509742QA (en) * | 2013-06-03 | 2015-12-30 | Novartis Ag | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| MX384919B (es) | 2014-11-26 | 2025-03-14 | Us Health | Receptores de células t de kras anti-mutado. |
| JP7185524B2 (ja) | 2015-09-15 | 2022-12-07 | アメリカ合衆国 | Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体 |
| WO2018026691A1 (en) * | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
-
2017
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active Active
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/it unknown
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2022
- 2022-09-29 CY CY20221100645T patent/CY1125601T1/el unknown
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/ja active Active
-
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
-
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/ja active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
-
2026
- 2026-01-15 AU AU2026200276A patent/AU2026200276A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050400A5 (https=) | ||
| JP2023025108A5 (https=) | ||
| JP3370324B2 (ja) | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 | |
| Sukhatme et al. | The T cell differentiation antigen Leu-2/T8 is homologous to immunoglobulin and T cell receptor variable regions | |
| CN114746440B (zh) | 新型多肽复合物 | |
| US5891996A (en) | Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use | |
| TWI801862B (zh) | 抗ｔｉｇｉｔ的抗體、其製備方法和應用 | |
| JP2020186248A5 (https=) | ||
| EP4501957A1 (en) | Anti-serum albumin nanobody and derivative thereof | |
| CN106029694A (zh) | 治疗性肽 | |
| AU2012252152A1 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| CN113631582A (zh) | 一种融合蛋白及其用途 | |
| JP2025063321A5 (https=) | ||
| JPWO2021241616A5 (https=) | ||
| Sanchez et al. | Structure of a third murine immunoglobulin lambda light chain variable region that is expressed in laboratory mice. | |
| JPWO2022224997A5 (https=) | ||
| Zezza et al. | Sequence of C region of L chains from Xenopus laevis Ig | |
| CN115991782A (zh) | 抗间皮素纳米抗体及其用途 | |
| JP2023550780A (ja) | 二重特異性抗体およびその用途 | |
| CN118119645A (zh) | 双功能融合蛋白及其用途 | |
| CA2443719A1 (en) | Human fibroblast growth factor-related compositions | |
| JP4059404B2 (ja) | 甲状腺機能を刺激する活性を持つ抗体 | |
| US20260109781A1 (en) | Anti-her2 antibodies and methods of use thereof | |
| Zhou et al. | cDNA sequence analysis of monoclonal antibodies against the human placental acidic isoferritin | |
| JP2024534824A (ja) | 操作された抗ｈｅｒ２二重特異性タンパク質 |